Thanks for clearing that up PoS - i guess it can also be assumed that once the discussions to expand the collaboration are finalised & the new agreement reached further milestones will be gained as the in-vivo test work will step into a further stage.....
And on this comment re: business model
"For any serious analysts this looks like being a text book business model that will get studied in years to come."
It is very intersting to note that Eli Lilly announced their new approach this week to share R&D costs by expanding the early stage pipeline yet not funding the entire bill. It appears very similar to PYC's approach although EL still hold significant risks as they fund a portion but they also position themselves with the ability to license candidates where as PYC fund very little yet are exposed to significant upside as the majors take the discoveries & inherit risk further. Funny that Eli Lilly highlight their new model with the same kicker that Phylogicas preso uses "more shots on goal". Maybe they've been looking at the company thats got their rivals attention perked up... lol
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)